Shanghai Medicilon Inc.

  On the way to fight against tumors, we may encounter many "enemies", and most of the time it is difficult to get through.  However, when faced with the formidable enemy of brain metastasis, they often lose.  Relevant data show that about 25%-40% of malignant tumors will develop brain metastasis during the course of the disease. Even with targeted therapy drugs, many will fail before they reach the metastasis. Why is brain metastasis so common and dangerous?  We have to mention the blood-brain barrier that blocks drugs from entering the brain. How to allow drugs to break through the blood-brain barrier is a major and important problem in the treatment of tumor brain metastasis.  Fortunately, there are always scientists who are not afraid of war and are bound to attack the blood-brain barrier and lead drugs across the blood-brain barrier. One of the examples is Dr. Chen Chen that we interviewed today.  As a scientist with more than 20 years of experience in central nervous sy

  As a CRO that advocates green drug research and development, Medicilon has always been committed to promoting the green upgrading of pharmaceutical processes through technological innovation. Medicilon has already used enzymes in process research and development, and relying on its strong chemical and biological background, Medicilon has established a the Enzyme Catalysis Technology Platform to screen catalytic enzymes for specific reaction types and establish corresponding enzyme libraries to assist process development and production. Medicilon Enzyme Catalysis Service Platform 01 Chemical Technology Platform Development of Pharmaceutical Intermediates and APls Functional Chemical Development 02 Biotechnology Platform Enzyme Development and Applications Enzyme Production 03 Quality Technology Platform Quality and Control Research Inspection and Testing Services Medicilon's Enzyme Catalysis Technology Platform includes chemical technology platform, biotechnology platform, and qu

Biologics have become a core component of many treatment strategies for rheumatic inflammation. Scientists often consider that immunogenicity is the important limiting factor in the early stages of development of biological agents. However, theoretical guidance is relatively limited and the determination methods for measuring immunogenicity are complex, making the development of past research difficult. But now, the emergence of biosimilars has sparked new interest in immunogenicity, the development of more accurate and convenient testing methods, a greater understanding of the pharmacokinetic results of immunogenicity, and comprehensive and specific guidelines from regulators. Rheumatologists’ overall understanding of the field has greatly improved, including  the factors that cause the immunogenicity, the potential clinical consequences, and the impact on daily treatment. All biological agents are immunogenic and many pathways affect their bioavailability, including patient-specific

  Immunogenicity testing   is focused on the detection and characterization of anti-drug antibodies (ADAs) and the determination whether these ADAs are neutralizing antibodies(NABs), as NABs may affect the   pharmacokinetics   (PK) of the drug.  It is clear however that animal studies are not considered relevant to predict immunogenicity in humans. Still, the selection of the mini-pig to explore their possibilities for immunogenicity testing of biopharmaceuticals, especially to assist in the interpretation of   safety studies , is based on the improved knowledge that various physiological aspects of Göttingen Minipigs® resemble more the human situation than other animal species.  It is expected therefore that in the near future the safety testing, including immunogenicity testing of biopharmaceuticals in mini-pigs will increase as an alternative for non human primate studies, which use will be limited or restricted. Immunogenicity Services Screening assays for detection of positive sam

  With flu season rapidly advancing, attention will shift to what novel ideas scientists have developed to protect public health. Now, it would seem investigators at the Dana-Farber Cancer Institute are looking to take the lead in this critical discussion because they have recently published data on the discovery of a new type of immune antibody that can evolve rapidly to neutralize a broad range of influenza virus strains—including those the body hasn’t yet encountered. The revelation of the body’s ability to make the adaptable antibody suggests potential strategies for creating improved or even universal influenza vaccines.                   ❖      Medicilon’s Antibody Development Technology Service Medicilon's antibody development technical service discount covers the full line of  ADA antibody development technical services  and druggable antibody development technical services. The 20% off discount applies to the completion of ADA rabbit polyclonal antibody development, ADA mo